Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Cited by (1,051)

Items 401–500 of 1,051

1. Pan-cancer deconvolution of tumour composition using DNA methylation
   Chakravarthy, Ankur, Furness, Andrew, Joshi, Kroopa, Ghorani, Ehsan, Ford, Kirsty, Ward, Matthew J., King, Emma V., Lechner, Matt, Marafioti, Teresa, Quezada, Sergio A. et al. · 2018 · Nature Communications
2. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
   Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen · 2022 · Nature Reviews Drug Discovery
3. Recent advances in triple negative breast cancer: the immunotherapy era
   Antonio Marra, Giulia Viale, Giuseppe Curigliano · 2019 · BMC Medicine
4. Metal Drugs and the Anticancer Immune Response
   Englinger, Bernhard, Pirker, Christine, Heffeter, Petra, Terenzi, Alessio, Kowol, Christian R., Keppler, Bernhard K., Berger, Walter · 2019 · Chemical Reviews
5. Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
   Albrecht Neeße, Christian Alexander Bauer, Daniel Öhlund, Matthias Lauth, Malte Buchholz, Patrick Michl, David A. Tuveson, Thomas Mathias Gress · 2018 · Gut
6. MHC-I Genotype Restricts the Oncogenic Mutational Landscape
   Rachel Marty, Saghar Kaabinejadian, David Rossell, Michael J. Slifker, Joris van de Haar, Hatice Billur Engin, Nicola de Prisco, Trey E. Ideker, William H. Hildebrand, Joan Font-Burgada et al. · 2017 · Cell
7. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
   Rui Kuai, Wenmin Yuan, Sejin Son, Jutaek Nam, Yao Xu, Yuchen Fan, Anna A. Schwendeman, James Jaehyun Moon · 2018 · Science Advances
8. TP53, STK11 , and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
   Jérôme Biton, Audrey Mansuet‐Lupo, Nicolas Pécuchet, Marco Alifano, Hanane Ouakrim, Jennifer Arrondeau, Pascaline Boudou, François Goldwasser, Karen Leroy, Jérémy Goc et al. · 2018 · Clinical Cancer Research
9. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
   Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ikuo Konishi · 2016 · International Journal of Clinical Oncology
10. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
    Fabiana Perna, Samuel Berman, Rajesh Kumar Soni, Jorge Mansilla‐Soto, Justin Eyquem, Mohamad Hamieh, Ronald C. Hendrickson, Cameron Brennan, Michel Sadelain · 2017 · Cancer Cell
11. Organoid technology and applications in cancer research
    Hanxiao Xu, Xiaodong Lyu, Ming Yi, Weiheng Zhao, Yongping Song, Kongming Wu · 2018 · Journal of Hematology & Oncology
12. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
    Barzin Y. Nabet, Mohammad Shahrokh Esfahani, Everett James Moding, Emily G. Hamilton, Jacob J. Chabon, Hira A. Rizvi, Chloé Beate Steen, Aadel A. Chaudhuri, Chih Long Liu, Angela Bik‐Yu Hui et al. · 2020 · Cell
13. Implementing TMB measurement in clinical practice: considerations on assay requirements
    Reinhard Büttner, John W. Longshore, Fernando López‐Ríos, Sabine Merkelbach‐Bruse, Nicola Normanno, Étienne Rouleau, Frederique Madeleine Penault-Llorca · 2019 · ESMO Open
14. Immunotherapy for lung cancer
    A. Kwilas Steven, Scott A. Fisher, Bruce W.S. Robinson · 2016 · Respirology
15. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
    Liisa Chang, Minna Chang, Hanna M. Chang, Fuju Chang · 2017 · Applied immunohistochemistry & molecular morphology
16. Understanding the tumor microenvironment for effective immunotherapy
    Sadeghi Rad, Habib, Monkman, James, Warkiani, Majid E., Ladwa, Rahul, O'Byrne, Ken, Rezaei, Nima, Kulasinghe, Arutha · 2021 · Medicinal Research Reviews
17. Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
    Chao Wang, Wujin Sun, Grace Wright, Andrew Zhuang Wang, Zhen Gu · 2016 · Advanced Materials
18. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
    Anand Rotte, Jiangtao Jin, Vincent Lemaire · 2017 · Annals of Oncology
19. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
    Alexandra Snyder, Tavi Nathanson, Samuel Aaron Funt, Arun Ahuja, Jacqueline L. Buros, Matthew David Hellmann, Eliza Chang, Bülent Arman Aksoy, Hikmat A Al‐Ahmadie, Erik C. Yusko et al. · 2017 · PLoS Medicine
20. Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy
    Constantinidou, Anastasia, Alifieris, Constantinos, Trafalis, Dimitrios T. · 2019 · Pharmacology & Therapeutics
21. Immune checkpoint inhibitors in challenging populations
    Johnson, Douglas B., Sullivan, Ryan J., Menzies, Alexander M. · 2017 · Cancer
22. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
    Brocks, David, Schmidt, Christopher R, Daskalakis, Michael, Jang, Hyo Sik, Shah, Nakul M, Li, Daofeng, Li, Jing, Zhang, Bo, Hou, Yiran, Laudato, Sara et al. · 2017 · Nature Genetics
23. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy
    Kaiyuan Ni, Guangxu Lan, Christina Chan, Bryan Quigley, Kuangda Lu, Theint Aung, Nining Guo, Patrick J. La Rivière, Ralph R. Weichselbaum, Wenbin Lin · 2018 · Nature Communications
24. High response rate to PD-1 blockade in desmoplastic melanomas
    Eroglu, Zeynep, Zaretsky, Jesse M., Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B., Liniker, Elizabeth, Ben Kong, Munhoz, Rodrigo, Rapisuwon, Suthee et al. · 2018 · Nature
25. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    E.J. Aguilar, Biagio Ricciuti, Justin F. Gainor, Kenneth L. Kehl, Sasha Kravets, Suzanne Eleanor Dahlberg, Mizuki Nishino, Lynette Marie Sholl, Anika E. Adeni, Safiya J. Subegdjo et al. · 2019 · Annals of Oncology
26. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
    Chabanon, Roman M., Muirhead, Gareth, Krastev, Dragomir B., Adam, Julien, Morel, Daphné, Garrido, Marlène, Lamb, Andrew, Hénon, Clémence, Dorvault, Nicolas, Rouanne, Mathieu et al. · 2019 · Journal of Clinical Investigation
27. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes
    Amalie Kai Bentzen, Andrea Marion Marquard, Rikke Lyngaa, Sunil Kumar Saini, Sofie Ramskov, Marco Donia, Lina Such, Andrew J.S. Furness, Nicholas McGranahan, Rachel Rosenthal et al. · 2016 · Nature Biotechnology
28. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
    Elizabeth R. Plimack, Joaquim Bellmunt B, Shilpa Gupta, Raanan Berger, Laura Q.M. Chow, Jonathan Wes Juco, Jared K. Lunceford, Sanatan Saraf, Rodolfo F. Perini, Peter H. O’Donnell · 2017 · The Lancet Oncology
29. Microenvironmental Determinants of Pancreatic Cancer
    Elisabeth Heßmann, S Buchholz, İhsan Ekin Demir, Shiv K. Singh, Thomas Mathias Gress, Volker Ellenrieder, Albrecht Neeße · 2020 · Physiological Reviews
30. The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
    Matteo Berti, David Cortez, Massimo Lopes · 2020 · Nature Reviews Molecular Cell Biology
31. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
    Verma, Vivek, Shrimali, Rajeev K, Ahmad, Shamim, Dai, Winjie, Wang, Hua, Lu, Sumin, Nandre, Rahul, Gaur, Pankaj, Lopez, Jose, Sade-Feldman, Moshe et al. · 2019 · Nature Immunology
32. Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
    Joseph Nicholas Bodor, Yanis Boumber, Hossein Borghaei · 2019 · Cancer
33. Breaking Down the Barriers to Precision Cancer Nanomedicine
    von Roemeling, Christina, Jiang, Wen, Chan, Charles K., Weissman, Irving L., Kim, Betty Y.S. · 2017 · Trends in Biotechnology
34. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers
    Michael David Offin, Hira A. Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Edward Dela Cruz Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus D. Schultz et al. · 2018 · Clinical Cancer Research
35. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
    Weijie Ma, Barbara M. Gilligan, Jianda D. Yuan, Tianhong Li · 2016 · Journal of Hematology & Oncology
36. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
    Ila J. Datar, Miguel F. Sanmamed, Jun Wang, Brian S. Henick, Jungmin Choi, Ti Badri, Weilai Dong, Nikita Lavanya Mani, Maria I Toki, Luis D. Mejías et al. · 2019 · Clinical Cancer Research
37. T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
    Smita S. Chandran, Christopher Austin Klebanoff · 2019 · Immunological Reviews
38. Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
    Okamura, Ryosuke, Boichard, Amélie, Kato, Shumei, Sicklick, Jason K., Bazhenova, Lyudmila, Kurzrock, Razelle · 2018 · JCO Precision Oncology
39. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas
    Natasha Rekhtman, Joseph Montecalvo, Jason C. Chang, Deepu Alex, Ryan N. Ptashkin, Ni Ai, Jennifer L. Sauter, Brie E. Kezlarian, Achim A. Jungbluth, Patrice Desmeules et al. · 2019 · Journal of Thoracic Oncology
40. Molecular chess? Hallmarks of anti-cancer drug resistance
    Ian A. Cree, Peter Charlton · 2017 · BMC Cancer
41. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Jordi Remón, Conor Ernst Steuer, Suresh S. Ramalingam, Enriqueta Felip · 2018 · Annals of Oncology
42. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
    Antoni Ribas, Donald P. Lawrence, Victoria G. Atkinson, Sachin Agarwal, Wilson H. Miller, Matteo Salvatore Carlino, Rosalie Anne Fisher, Georgina Venetia Long, Frank Stephen Hodi, Jennifer Tsoi et al. · 2019 · Nature Medicine
43. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
    A.J. Schoenfeld, H. Rizvi, Chai Bandlamudi, Jennifer L. Sauter, William David Travis, Natasha Rekhtman, Andrew J. Plodkowski, Rocío Pérez-Johnston, Peter Sawan, Amanda Beras et al. · 2020 · Annals of Oncology
44. Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
    Kailin Yang, Ahmed Halima, Timothy An-thy Chan · 2023 · Nature Reviews Clinical Oncology
45. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
    Li Liu, Xue Bai, Jian Wang, Xin-Ran Tang, Dehua Wu, Shasha Du, Xiuju Du, Yaowei Zhang, Hongbo Zhu, Yuan Fang et al. · 2019 · Clinical Cancer Research
46. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
    Joshua K. Sabari, Giulia Costanza Leonardi, Catherine A. Shu, Renato Umeton, Joseph Montecalvo, Ai Ni, R. Chen, Jordan Dienstag, Chebli Mrad, Isabella Bergagnini et al. · 2018 · Annals of Oncology
47. Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
    Amrita B Basu, Ganesan Ramamoorthi, Gabriella K. Albert, Corey Gallen, Amber Beyer, Colin Snyder, Gary K. Koski, Mary Lenora Disis, Brian J. Czerniecki, Krithika Nandakumar Kodumudi · 2021 · Frontiers in Immunology
48. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
    Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, R. Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin David Forster, I. Monnet et al. · 2021 · Journal of Thoracic Oncology
49. Lower Airway Dysbiosis Affects Lung Cancer Progression
    Tsay, Jun-Chieh J., Wu, Benjamin G., Sulaiman, Imran, Gershner, Katherine, Schluger, Rosemary, Li, Yonghua, Yie, Ting-An, Meyn, Peter, Olsen, Evan, Perez, Luisannay et al. · 2021 · Cancer Discovery
50. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
    Hakozaki, Taiki, Richard, Corentin, Elkrief, Arielle, Hosomi, Yukio, Benlaïfaoui, Myriam, Mimpen, Iris, Terrisse, Safae, Derosa, Lisa, Zitvogel, Laurence, Routy, Bertrand et al. · 2020 · Cancer Immunology Research
51. Biomarkers of response to PD-1/PD-L1 inhibition
    Saman Maleki Vareki, Carmen Garrigós, Ignacio Durán · 2017 · Critical Reviews in Oncology/Hematology
52. Dendritic cells as shepherds of T cell immunity in cancer
    Mikaël J. Pittet, Mauro Di Pilato, Christopher Garris, Thorsten R. Mempel · 2023 · Immunity
53. Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer
    Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M. Kass, Maria Jasin · 2017 · Annual Review of Cancer Biology
54. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
    Robert S. Brody, Yiduo Zhang, Marc S. Ballas, Mohd Kashif Siddiqui, Palvi Gupta, Craig Barker, Anita Midha, Jill Walker · 2017 · Lung Cancer
55. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
    Guizhi Zhu, Geoffrey M. Lynn, Orit Jacobson, Kai Chen, Yi Liu, Huimin Zhang, Ying Ma, Fuwu Zhang, Rui Tian, Qianqian Ni et al. · 2017 · Nature Communications
56. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
    Daixi Ren, Yuze Hua, Boyao Yu, Xin Ye, Ziheng He, Chunwei Li, Jie Wang, Yongzhen Mo, Xiaoxu Wei, Yunhua Chen et al. · 2020 · Molecular Cancer
57. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
    Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah J. Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé Beate Steen, Bogdan A. Luca et al. · 2022 · Nature Medicine
58. Tissue-specific tumorigenesis: context matters
    Günter Schneider, Marc Schmidt‐Supprian, Roland Rad, Dieter Saur · 2017 · Nature reviews. Cancer
59. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
    Stephen Joseph Bagley, Arati Suvas Desai, Gerald P. Linette, Carl H. June, Donald M. O’Rourke · 2018 · Neuro-Oncology
60. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
    Topalian, Suzanne L., Forde, Patrick M., Emens, Leisha A., Yarchoan, Mark, Smith, Kellie N., Pardoll, Drew M. · 2023 · Cancer Cell
61. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
    Shixiang Wang, Zaoke He, Xuan Wang, Huimin Li, Xuesong Liu · 2019 · eLife
62. KRAS-Mutant non-small cell lung cancer: From biology to therapy
    Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William J. John, Luis G Paz-Ares, Gerald Schmid‐Bindert · 2018 · Lung Cancer
63. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
    Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci, Luca Mazzarella · 2019 · Journal for ImmunoTherapy of Cancer
64. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
    Sarah Derks, Xiaoyun Liao, Anna Maria Chiaravalli, Xinsen Xu, Maria Constanza Camargo, Enrico Solcia, Fausto Sessa, Tania Fleitas, Gordon James Freeman, Scott J. Rodig et al. · 2016 · Oncotarget
65. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
    Diego Chowell, Chirag Krishna, Federica Pierini, Vladimir Makarov, Naiyer A. Rizvi, Fengshen Kuo, Luc G.T. Morris, Nadeem Riaz, Tobias L. Lenz, Timothy An-thy Chan · 2019 · Nature Medicine
66. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
    Brendan K Bulik-Sullivan, Jennifer Busby, Christine D. Palmer, Matthew J. Davis, Tyler Murphy, Andrew Clark, Michele Busby, Fujiko F. Duke, Aaron Yang, Lauren Young et al. · 2018 · Nature Biotechnology
67. Immunotherapy for head and neck cancer: Recent advances and future directions
    John D. Cramer, Barbara Ann Burtness, Robert Louis Ferris · 2019 · Oral Oncology
68. Chimeric antigen receptor T cells: a novel therapy for solid tumors
    Shengnan Yu, Anping Li, Qian Liu, Tengfei Li, Xun Yuan, Xinwei Han, Kongming Wu · 2017 · Journal of Hematology & Oncology
69. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
    Navid Sobhani, Dana Rae Tardiel-Cyril, Aram Davtyan, Daniele Generali, Raheleh Roudi, Yong Li · 2021 · Cancers
70. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
    Mansi Saxena, Nina Bhardwaj · 2018 · Trends in cancer
71. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
    H. Raza Ali, Silvia-Elena Glont, Fiona M. Blows, Elena Provenzano, Sarah‐Jane Dawson, B. Liu, Louise Hiller, Janet Dunn, C. J. Poole, Sarah Jane Bowden et al. · 2015 · Annals of Oncology
72. The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
    Alexander Noor Shoushtari, Rodrigo Ramella Munhoz, Deborah Kuk, Patrick Alexander Ott, Douglas Buckner Johnson, Katy K. Tsai, Suthee Rapisuwon, Zeynep Eroglu, Ryan Joseph Sullivan, Jason J. Luke et al. · 2016 · Cancer
73. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
    Takuro Noguchi, Jeffrey P. Ward, Matthew M. Gubin, Cora D. Arthur, Sang Hun Lee, Jasreet Hundal, Mark J. Selby, Robert F. Graziano, Elaine R. Mardis, Alan J. Korman et al. · 2017 · Cancer Immunology Research
74. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
    Luc G.T. Morris, Nadeem Riaz, Alexis Desrichard, Yasin Şenbabaoğlu, A. Ari Hakimi, Vladimir Makarov, Jorge Sergio Reis-Filho, Timothy An-thy Chan · 2016 · Oncotarget
75. PD-1 and PD-L1 antibodies in cancer: current status and future directions
    Arjun Vasant Balar, Jeffrey S. Weber · 2017 · Cancer Immunology Immunotherapy
76. Targeting the DNA damage response in immuno-oncology: developments and opportunities
    Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, Jean‐Charles Soria, Philippe Pasero, Sophie C. Postel-Vinay · 2021 · Nature reviews. Cancer
77. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures
    Joo Sang Lee, Lital N. Adler, Hiren Karathia, Narin Nard Carmel, Shiran Rabinovich, Noam Auslander, Rom Keshet, Noa Stettner, Alon Silberman, Lilach Agemy et al. · 2018 · Cell
78. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment
    Haist, Maximilian, Stege, Henner, Grabbe, Stephan, Bros, Matthias · 2021 · Cancers
79. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
    Koji Haratani, Hidetoshi Hayashi, Taro Tanaka, Hiroyasu Kaneda, Yosuke Togashi, Kazuko Sakai, K. Hayashi, Shuta Tomida, Yasutaka Chiba, Kimio Yonesaka et al. · 2017 · Annals of Oncology
80. WNT Signaling and Colorectal Cancer
    Emma M. Schatoff, Benjamin I. Leach, Lukas E. Dow · 2017 · Current Colorectal Cancer Reports
81. The intracellular signalosome of PD-L1 in cancer cells
    David Escors, María Gato, Miren Zuazo, Hugo Arasanz, María Jesús García-Granda, Ruth Vera, Grazyna T. Kochan · 2018 · Signal Transduction and Targeted Therapy
82. Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
    Florian Guisier, Catherine Dubos‐Arvis, Florent Vinas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, P. Fournel, R. Lamy et al. · 2020 · Journal of Thoracic Oncology
83. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
    Chalabi, M., Cardona, A., Nagarkar, D.R., Dhawahir Scala, A., Gandara, D.R., Rittmeyer, A., Albert, M.L., Powles, T., Kok, M., Herrera, F.G. · 2020 · Annals of Oncology
84. Immunotherapy, Inflammation and Colorectal Cancer
    Charles Robert Lichtenstern, Rachael Katie Ngu, Shabnam Shalapour, Michael Karin · 2020 · Cells
85. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
    Marcelo Vailati Negrao, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y. Elamin et al. · 2021 · Journal for ImmunoTherapy of Cancer
86. Deep learning-based prediction of the T cell receptor–antigen binding specificity
    Lu, Tianshi, Zhang, Ze, Zhu, James, Wang, Yunguan, Jiang, Peixin, Xiao, Xue, Bernatchez, Chantale, Heymach, John V., Gibbons, Don L., Wang, Jun et al. · 2021 · Nature Machine Intelligence
87. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
    Ioannis Zerdes, Alexios Matikas, Jonas C. S. Bergh, George Z. Rassidakis, Theodoros Foukakis · 2018 · Oncogene
88. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer
    Eri Sugiyama, Yosuke Togashi, Yoshiko Takeuchi, Sayoko Shinya, Yasuko Tada, Keisuke Kataoka, Kenta Tane, Eiichi Sato, Genichiro Ishii, Kōichi Goto et al. · 2020 · Science Immunology
89. Lung cancer in patients who have never smoked — an emerging disease
    Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, Pasi Antero Janne · 2024 · Nature Reviews Clinical Oncology
90. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
    Stefani Spranger · 2016 · International Immunology
91. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
    Y.-L. Wu, D. Planchard, Shun Lü, Hao Sun, N. Yamamoto, Dongwook Kim, Daniel Shao-Weng Tan, James Chih‐Hsin Yang, M. Azrif, Tetsuya Mitsudomi et al. · 2018 · Annals of Oncology
92. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
    Zijun Yidan Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young · 2017 · Frontiers in Immunology
93. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance
    Gh. Rasool Bhat, Itty Sethi, Hana Q. Sadida, Bilal Rah, Rashid Mir, Naseh A. Algehainy, Ibrahim Altedlawi Albalawi, Tariq Masoodi, Gowtham Kumar Subbaraj, Farrukh Jamal et al. · 2024 · Cancer and Metastasis Reviews
94. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
    Matthew W. Rosenbaum, Jacob R. Bledsoe, Vicente Morales‐Oyarvide, Tiffany G. Huynh, Mari A. Mino-Kenudson · 2016 · Modern Pathology
95. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
    Tanner Michael Johanns, Christopher A. Miller, Ian G. Dorward, Christina I. Tsien, Edward F. Chang, Arie Perry, Ravindra Uppaluri, Cole Ferguson, Robert E. Schmidt, Sonika M Dahiya et al. · 2016 · Cancer Discovery
96. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
    Jenny Lee, Elena Shklovskaya, Su Yin Lim, Matteo Salvatore Carlino, Alexander Maxwell Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Yee Hwa Yang et al. · 2020 · Nature Communications
97. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
    Ju‐Yeun Lee, Hyun Tae Lee, Woori Shin, Jongseok Chae, Jaemo Choi, Sung Hyun Kim, Heejin Lim, Tae Won Heo, Kyeong Young Park, Yeon Ji Lee et al. · 2016 · Nature Communications
98. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer
    Xiaomeng Dai, Lisen Lu, Suke Deng, Jingshu Meng, Chao Wan, Jing Huang, Yajie Sun, Yan Hu, Bian Wu, Gang Wu et al. · 2020 · Theranostics
99. Scientific Advances in Lung Cancer 2015
    Tsao, Anne S., Scagliotti, Giorgio V., Bunn, Paul A., Carbone, David P., Warren, Graham W., Bai, Chunxue, de Koning, Harry J., Yousaf-Khan, A. Uraujh, McWilliams, Annette, Tsao, Ming Sound et al. · 2016 · Journal of Thoracic Oncology
100. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
     Xin Wang, Gaochao Guo, Hui Guan, Yang Yu, Jie Lu, Jinming Yu · 2019 · Journal of Experimental & Clinical Cancer Research